London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice update. Step by sure step we are really starting to make some headway.
Good update, holding with little choice but you never know anyway!!! £1 Kenny this time next year! Gla
Apollon Formularies says new Jamaica facility produces 20-litres of high-quality cannabis oil a day
"There is an increasing global demand for medical cannabis oils, and I believe the oils that will be most sought after will be those that have been validated in pre-clinical and clinical patent data that demonstrates successful results and not just random generic oils with no clinical testing," said chief executive, Dr Stephen Barnhill
https://www.proactiveinvestors.co.uk/companies/news/969277/apollon-formularies-says-new-jamaica-facility-produces-20-litres-of-high-quality-cannabis-oil-a-day-969277.html
"There is an increasing global demand for medical cannabis oils, and I believe the oils that will be most sought after will be those that have been validated in pre-clinical and clinical patent data that demonstrates successful results and not just random generic oils with no clinical testing. " stated Stephen D. Barnhill, MD, Chairman and CEO of Apollon Formularies, plc, "Our goal, as a Cannabis Licensing Authority (CLA) licensed processing facility, is to produce large amounts of the highest quality medicinal cannabis products with demonstrated successful clinical results for the medical patients in Jamaica and export for patients in other countries where legal import is allowed. This new high-volume processing laboratory will allow us to achieve that goal."
Dr. Herbert Fritsche, Apollon's Chief Science Officer, and Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas stated, "In addition to significantly increasing our inventory for legal export, the high-volume processing laboratory also allows us to produce and store large volumes of our medical cannabis products for additional clinical trials to be performed by potential pharmaceutical partners, as may be required for legal approval in their jurisdictions. Having this increased inventory of analytically validated cannabis oil readily available, allows our potential partners to perform clinical trials in a reduced timeframe and have confidence in the consistency of product and the dose amounts established from those clinical trials."
Director of Research Development and Communications at the Cannabis Licensing Authority (CLA), Felicia Bailey, says the agency is committed to facilitating the import and export of cannabis until the import/export regulations are promulgated. Under the Interim Measures, licensees can export cannabis inflorescence/buds and extracts from Jamaica to jurisdictions across the world. CLA licensees have exported to countries such as Canada, Australia, Israel, Zimbabwe, and the Cayman Islands. "Getting into the global space is what we are aiming for, as becoming global players is very important, and that is why we are doing all that we can to ensure that our licensees have that ability to export and they have been taking advantage of that opportunity," said Ms. Bailey at a recent JIS Think Tank7
Jeff Nagel, Director of Processing and Product Manufacturing for Apollon, commented, "I want to congratulate our extraction team for their efforts in completing this new state-of-the-art processing laboratory and their dedication to producing the highest quality medical cannabis oils for our patients", Mr. Nagel continued, "The Jamaican landrace strains are giving us a very nice spectrum of not only THC and CBD but high levels of minor cannabinoids such as CBC, CBG and THCV for our medical cannabis formulations."
Apollon Formularies Completes High-Volume Processing Laboratory
In Preparation for International Export of Medical Cannabis Products
• Apollon Formularies completes state-of-the-art high-volume processing laboratory
• Increased processing capacity to 20 Litres per day of analytically validated medical cannabis oil
• Apollon to significantly increase its inventory in preparation for global export
• Increased capacity provides readily available inventory for potential pharmaceutical partners to perform independent clinical trial validation
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on AQSE Growth Market, is pleased to announce the completion of its high-volume medical cannabis extract processing facility in Negril, Jamaica. This new state-of-the-art facility has the capacity to produce more than 20 litres of full spectrum medical cannabis oil per day, allowing Apollon to significantly increase its inventory in preparation for global export to those countries where legal import is allowed, and to have sufficient amounts of medical cannabis products available for potential pharmaceutical partners to perform independent clinical trial validation.
Apollon's proprietary medical cannabis products were recently shown in pre-clinical 3rd party, independent testing at BIOENSIS laboratories in the United States to be highly effective in killing cancer cells using state-of-the-art 3D cell culture testing. The successful BIOENSIS results in breast cancer and prostate cancer were previously announced by the Company. ¹ ² ³
Apollon's medical cannabis products are now available to patients by physician prescription and for clinical trials at the International Cancer and Chronic Pain Institute in Kingston, Jamaica. Apollon's research goal is to collect clinical outcomes data on these patients to document the treatment success predicted in its pre-clinical testing.
According to a recently published Allied Market Research report, the global medical cannabis industry generated $6.82 billion in 2020, and is expected to reach $53.88 billion by 2030, witnessing a CAGR of 23.6% from 2021 to 2030.4 Market revenue growth can be attributed to the increasing use of medical cannabis to treat diseases and conditions, rising research and development activities, and legalization of cannabis in various countries across the globe.4 The key factors driving this market is the increasing adoption of medical cannabis for the treatment of chronic diseases like arthritis, Alzheimer's, and cancer along with mental disorders such as depression, anxiety, and epilepsy.5 Another factor anticipated to propel the market growth is the rising legalization of medical cannabis in various countries that enables easy access of the drugs to patients.5
The oil segment held the largest revenue share in the cannabis extract market and was valued at USD 4.
Apollon Formularies
@apollon_uk
·
16m
Apollon's proprietary medical cannabis products were recently shown in pre-clinical 3rd party, independent testing at BIOENSIS laboratories in the United States to be highly effective in killing cancer cells using state-of-the-art 3D cell culture testing.
Apollon Formularies
@apollon_uk
·
1h
"There is an increasing global demand for medical cannabis oils, and I believe the oils that will be most sought after will be those that have been validated in pre-clinical and clinical patent data that demonstrates successful results"
Apollon Formularies
@apollon_uk
·
2h
Apollon Formularies Completes High-Volume Processing Laboratory In Preparation for International Export of Medical Cannabis Products
https://twitter.com/apollon_uk
And still very slow action.............. IMHO
Proceeds will be used to, among other things, scale up operations, identify international customers for its high quality oils,
https://www.investegate.co.uk/apollon-formularies-plc--apol-/prn/admission-to-trading-on-aqse-and-apollon-ltd-consent/20210413070000P5E9A/
Tweet removed now.................. DYOR
9 mins ago..................
Apollon Formularies
@apollon_uk
·
9m
Apollon’s Research & Development Licence allows drug discovery using THC and other cannabinoids.
This allows Apollon to be the rare European listed company conducting medically supervised trials using THC to develop new therapeutics.
#APOL #AQSE
https://twitter.com/apollon_uk
The establishment of a legal market for medicinal cannabis in Jamaica via the passage of the Dangerous Drugs Amendment Act (DDAA) 2015 was lauded as a significant economic opportunity for Jamaica’s developing economy, with the potential to contribute export earnings, attract foreign investment and encourage cannabis tourism. Under the DDAA, a new government agency (Cannabis Licensing Authority, CLA) was established with a mandate of developing detailed regulations for the new industry, issuing licenses, and monitoring the compliance of licensed operators with regulatory requirements. The DDAA does not restrict the medical conditions that qualify for a doctor’s recommendation to legally obtain medicinal cannabis or the types of products that can be sold via CLA-licensed outlets. ¹ Apollon Formularies Jamaica is proud to be an established CLA-licensed company.
https://businesscann.com/first-cancer-patients-treated-with-apollon-formularies-products-at-the-international-cancer-and-chronic-pain-institute/
Jamaican physician with training in both Clinical Oncology and Palliative Medicine. Senior Medical Officer of the Hope Institute Hospital, Jamaica's only dedicated Oncology and Palliative Care Unit, and is an Associate Lecturer at the University of the West Indies in Kingston, Jamaica. Cofounder of the Jamaica Cancer Care and Research Institute (JACCRI), a nonprofit organization dedicated to improving the quality of cancer care and palliative care in Jamaica and the Caribbean, and is a Board Member of the International Association for Hospice and Palliative Care (IAHPC). Trained in Shamanic Energy Medicine, and has also studied acupuncture, homeopathy and Reiki. Advisor to the Endwell Project and research interests in the use of plant-based medicines such as cannabinoids and psychedelics for holistic symptom relief for people with palliative care needs.
https://jm.linkedin.com/in/dingle-spence-9557b434
A Jamaican medical centre in London, England, is now using cannabis-based therapies to treat cancer patients.
The centre is operated by Apollon Formularies and its medical team, led by Dr Margaret Dingle Spence, is reportedly seeing positive results during clinical trials.
“This is a huge milestone for Apollon,” said Stephen Barnhill, Apollon chairman and chief executive. “After many years of researching, developing, manufacturing and testing these proprietary Apollon medical cannabis formulations, we are so proud to announce that they are now available to cancer patients by physician prescription at the International Cancer and Chronic Pain Institute.”
The company's formulations, using state-of-the-art 3D cell culture testing, were recently shown to be highly effective in killing cancer cells in a pre-clinical assessment by BIOENSIS in the United States.
In addition to now treating international and local Jamaican patients, the institute's physicians intend to initiate clinical trials on Apollon's proprietary medical cannabis products.
This will be done through Apollon's Cannabis Licensing Authority (CLA) licence with the approval and oversight of the Ministry of Health and Wellness in Jamaica.
The company said that all cancer patients will be treated by experienced specialist physicians with additional expertise in cannabinoid medicine, led by Dr Spence, an oncologist and the medical director of the International Cancer and Chronic Pain Centre in Kingston, Jamaica.
The doctors will be exclusively prescribing Apollon products for patients being treated with medical cannabis.
Apollon Formularies, which trades on Aquis Stock Exchange in the UK, specialises in cutting-edge research and treatment of patients with cancer and chronic pain.
The company reports that it holds a suite of CLA licences allowing it to work with full spectrum oils inclusive of high levels of tetrahydrocannabinol, the main psychoactive compound in cannabis that produces the high sensation.
Apollon said its medical cannabis formulations are available by prescription to any licensed Jamaican doctor for their patients and for export to any country allowing legal import.
https://www.jamaicaobserver.com/news/j-can-company-using-cannabis-based-therapies-to-treat-cancer-patients_238540?profile=1338&template=MobileArticle
PRESS RELEASESDECEMBER 9, 2021
First Cancer Patients Treated With Apollon Formularies Products At The International Cancer and Chronic Pain Institute Apollon Formularies Plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on Aquis Stock Exchange, is...
https://businesscann.com/category/events/
https://businesscann.com/medical-cannabis-access-bill-to-be-debated-by-uk-parliament-today/
MOVES to boost medical cannabis access to UK patients are set to be discussed in parliament today.
Labour Party MP Jeff Smith’s Medical Cannabis Access Bill is set for its Second Reading in the lower chamber; the House of Commons.
The Bill proposes allowing cannabis medicines to be prescribed by the nation’s 50,000-plus GPs rather than solely specialist doctors.
It also proposes establishing a Commission on Cannabis-Based Medicines which will be empowered to implement ‘measures to overcome barriers to access in England and Wales’ within six months of the bill being passed into law
The first patients have begun treatment with medical cannabis formulations, which were found to be effective in killing cancer cells.
Apollon Formularies announced that its International Cancer and Chronic Pain Institute is now open and has welcomed the first cancer patients to be treated with the company’s proprietary medical cannabis products.
The UK-based medical cannabis pharmaceutical company’s products were recently shown to be highly effective in killing cancer cells, using state-of-the-art 3D cell culture testing.
Earlier this year, third-party testing showed that Apollon’s medical cannabis formulations were “particularly effective” in killing living HER2+ cancer cells, the cause of around 20 percent of all breast cancers.
Laboratory testing results also demonstrated that the formulations were effective in killing almost 100 per cent of living hormone-sensitive and hormone-resistant prostate cancer cells.
The company announced its plans to make the formulations available to licensed physicians to begin treating cancer patients in Jamaica.
https://cannabishealthnews.co.uk/2021/12/09/milestone-as-first-cancer-patients-treated-with-medical-cannabis-formulations/
Apollon Formularies
@apollon_uk
·
1h
Great to see that #Apollon’s milestone achievement of its first patients being admitted at its new International Cancer and Chronic Pain institute has been featured in
@CannabisHnews
. Read the article below ?? $APOL #MedicalCannabis
MrTHC........ Thanks for the assist............... :+)
no not me. I have small shares. Maybe I buy more soon.
THC....................... :+)
Apollon Formularies is an international medical cannabis pharmaceutical company specialising in cutting edge research and treatment of patients with cancer and chronic pain. Apollon is federally legal, licensed by the Cannabis Licensing Authority (CLA) in Jamaica, holds a suite of CLA licences which allow the company to work with full spectrum oils inclusive of high levels of THC.
Welcome back m8 take it yours was the 12.5k trade, is that correct...................
good to see some life in the old girl!!
hopefully more to come!!
Date & Time Volume Price
09.12.21 | 16:31:57 500000 2.5
08.12.21 | 16:27:11 66499 2.2
03.12.21 | 11:25:11 100000 2
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=APOL
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
09-Dec-21 16:31:57 2.50 500,000 Sell* 2.60 3.00 12.50k O
08-Dec-21 16:27:11 2.20 66,499 Unknown* 2.60 2.80 1,463 O
08-Dec-21 16:27:11 2.20 -66,999 Unknown* 2.60 2.80 -1,474